Latest Analysis stories from Opinion.
Strategic angle: A research team led by Potsdam-based bioinformatician Prof. Dr. Zoran Nikoloski has developed a computational approach and an accompanying tool for detailed analysis of actin filamentous structures in plants.
Strategic angle: We've got you covered for all of Sunday's action, from pregame keys to postgame analysis for UConn, Duke, Notre Dame and UCLA.
Strategic angle: Peaches, strawberries and grapes were almost always found to be contaminated with ‘forever chemicals’ in the analysis.
Strategic angle: An analysis reveals that drugmakers penalized for kickbacks paid only a small fraction of their U.S. revenue from the drugs involved.
Strategic angle: All the rankings, projections, cheat sheets, strategy and analysis you need for the 2026 fantasy baseball season.
Strategic angle: Exploring the rise of regional tensions in American politics.
Strategic angle: Much of the damage was caused in initial retaliatory strikes by Iran in the week after the US and Israel launched its operation.
Strategic angle: Inequality in wealth between men and women persists, impacting women's overall well-being.
Strategic angle: Academic freedom continues to decline worldwide, with significant implications for U.S. universities.
Strategic angle: A new approach to enhance conversational data analysis agents for various domains.
Strategic angle: All the talking points and in-depth analysis from the final round of the 2026 Six Nations.
Strategic angle: A deep dive into the implications of Trump's policies on Iran's nuclear ambitions.
Strategic angle: An in-depth analysis of the future of nuclear energy in Indonesia.
Strategic angle: Australia Institute data reveals a 10% increase in state and federal subsidies for fossil fuels, outpacing funding for the NDIS.
Strategic angle: Free speech on university campuses is a perennially hot topic, especially in light of recent protests.
Strategic angle: Understanding and managing pathological demand avoidance in children.
Strategic angle: The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% over the past five years, according to a new analysis.
Strategic implications in focus: Half of nations have met a UN deadline to report on how they are tackling biodiversity loss.